Thrombotic microangiopathy in children

Česká verzia

Authors: T. Šuláková ¹; T. Zaoral ¹; T. Seeman ^1,2
Authors place of work: Klinika dětského lékařství LF OU a FN Ostrava ¹; Pediatrická klinika 2. LF UK Praha ²
Published in the journal: Transfuze Hematol. dnes,30, 2024, No. S1, p. 16-29.
Category:
doi: https://doi.org/10.48095/cctahd2024suppl1S16

Summary

Thrombotic microangiopathy (TMA) is a pathological lesion triggered by endothelial injury or dysfunction. TMA occurs in a wide range of diseases and is characterized by microangiopathic haemolytic anaemia, thrombocytopenia and ischemic organ injury due to thrombosis in the microvascular capillary bed. In the paediatric population, TMA occurs in both as a primary, i.e. congenital form, and a secondary, acquired form – especially linked to E. coli infection. Understanding the epidemiology, pathophysiology, laboratory and clinical signs and differential diagnosis is crucial for a timely specific therapeutic approach to this life-threatening disease.

Keywords:

Adolescents – thrombotic thrombocytopenic purpura – haemolytic uremic syndrome – thrombotic microangiopathy – children

Zdroje

1. Loirat Ch, Fakhouri F, Ariceta G, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Ped Nephrol. 2016; 31 (1): 15–39. doi: 10.1007/s00467-015-3076-8.

2. Campistol J, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document: diagnóstico y tratamiento. Documento de consenso. Nefrología. 2015; 35 (5): 421–447. doi: 10.1016/j.nefro.2015.07.005.

3. Seeman T, Janda J. Dětská nefrologie. 2., přepracované a doplněné vydání. Praha: Grada Publishing, 2021. ISBN 978-80-271- 3283-6.

4. Genest D, Patriquin Ch, Licht Ch, John R, Reich H. Renal thrombotic microangiopathy: a review. Am J Kidney Dis. 2023; 81 (5): 591–605. doi: 10.1053/j.ajkd.2022.10.014

5. Azoulay E, Knoebl P, Garnacho-Montero J, et al. Expert statements on the standard of care in critically Ill adult patients with atypical hemolytic uremic syndrome. Chest. 2017; 152 (2): 424–434. doi: 10.1016/j.chest.2017.03.055.

6. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med. 2013; 368 (23): 2169–2181. doi: 10.1056/ NEJMoa1208981.

7. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2013; 8 (4): 554–562. doi: 10.2215/CJN.047 60512.

8. Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Ped. 2014; 2. doi: 10.3389/fped.2014.00097.

9. Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Ped Nephrol. 2019; 34 (8): 1337–1348. doi: 10.1007/s00467-018-4039-7.

10. Fidan K, Göknar N, Gülhan B, et al. Extra-Renal manifestations of atypical hemolytic uremic syndrome in children. Ped Nephrol. 2018; 33 (8): 1395–1403. doi: 10.1007/s004 67-018-3933-3.

11. Gumulec J, Lánská M, Hrachovinová I, et al. Trombotické mikroangiopatie – dostupnost diagnostických metod a léčebných možností v ČR v roce 2021: výsledky syndikovaného průzkumu mezi klinickými hematology. Transfuze Hematol Dnes. 2023; 29 (3): 37–315.

12. Gordon C, Chitalia V, Sloan J, et al. Thrombotic microangiopathy: a multidisciplinary team approach. Am J Kidney Dis. 2017; 70 (5): 715–721. doi: 10.1053/j.ajkd.2017.05.017.

13. Uriol Rivera M, Cabello Pelegrin S, Ballester Ruiz C, et al. Impact of a multidisciplinary team for the management of thrombotic microangiopathy. PLOS ONE. 2018; 13 (11): 206558. doi: 10.1371/journal.pone.0206558.

14. Schaefer F, Ardissino G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018; 94 (2): 408–418. doi: 10.1016/ j.kint.2018.02.029.

15. Noone D, Riedl M, Licht Ch. The role of von Willebrand factor in thrombotic microangiopathy. Ped Nephrol. 2018; 33 (8): 1297–1307. doi: 10.1007/s00467-017-3744-y.

16. Van Dorland H, Taleghani M, Sakai K, et al. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019; 104 (10): 2107–2115. doi: 10.3324/haematol. 2019.216796.

17. Joly B, Coppo P, Veyradier A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Exp Rev Hematol. 2019; 12 (6): 383–395. doi: 10.1080/17474086.2019.1611423.

18. Lotta L, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Human Mutation. 2010; 31 (1): 11–19. doi: 10.1002/humu.21143.

19. Joly B, Boisseau P, Roose P, et al. ADAMTS13 gene mutations influence ADAMTS13 conformation and disease age-onset in the French cohort of Upshaw–Schulman syndrome. Thromb Haemost. 2018; 118 (11): 1902–1917. doi: 10.1055/s-00 38-1673686.

20. Mariotte E, Azoulay E, Galicier L, et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016; 3 (5): 237–245. doi: 10.1016/S2352-3026 (16) 3 0018-7.

21. Joly B, Stepanian A, Leblanc T, et al. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French National Registry for Thrombotic Microangiopathy. Lancet Haematol. 2016; 3 (11): 537–546. doi: 10.1016/S2352-3026 (16) 30 125-9.

22. Mise K, Ubara Y, Matsumoto M, et al. Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report. BMC Nephrol. 2013; 14 (1): 156. doi: 10.1186/1471-2369-14-156.

23. Zheng X, Vesely S, Cataland S, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020; 18 (10): 2486–2495. doi: 10.1111/jth.15 006.

24. Joly BS, Coppo P, Veyradier A. Pediatric thrombotic thrombocytopenic purpura. Eur J Haematol. 2018; 101 (4): 425–434. doi: 10.1111/ ejh.13107.

25. Crawley J, Scully M. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology. 2013; 2013 (1): 292–299. doi: 10.1182/asheduca- tion-2013.1.292.

26. Bergstrand M, Hansson E, Delaey B, Callewaert F, De Passos Sousa R, Sargentini-Maier M. Caplacizumab model‐based dosing recommendations in pediatric patients with acquired thrombotic thrombocytopenic purpura. J Clin Pharmacol. 2022; 62 (3): 409–421. doi: 10.1002/jcph.1991.

27. Tarasco E, Bütikofer L, Friedman K, et al. Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. Blood. 2021; 137 (25): 3563–3575. doi: 10.1182/blood.2020009801.

28. Borogovac A, Reese J, Gupta S, George J. Morbidities and mortality in patients with hereditary thrombotic thrombocytopenic purpura. Blood Adv. 2022; 6 (3): 750–759. doi: 10.1182/bloodadvances.2021005760.

29. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5 (10): 1844–1859. doi: 10.2215/CJN. 022 10310.

30. Yerigeri K, Kadatane S, Mongan K, et al. Atypical hemolytic-uremic syndrome: genetic basis, clinical manifestations, and a multidisciplinary approach to management. J Multidisc Healthcare. 2023; 16: 2233–2249. doi: 10.2147/JMDH.S245620.

31. Sellier-Leclerc A-L, Fremeaux-Bacchi V, Dragon-Durey M-A, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007; 18 (8): 2392–2400. doi: 10.1681/ASN.2006080811.

32. Sallée M, Ismail K, Fakhouri F, et al. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol. 2013; 14 (1). doi: 10.1186/1471-2369-14-3.

33. Štolbová Š, Bezdíčka M, Seeman T, et al. Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children. Eur J Ped. 2020; 179 (11): 1739–1750. doi: 10.1007/ s00431-020-03666-9.

34. Raina R, Sethi S, Dragon-Durey M-A, et al. Systematic review of atypical hemolytic uremic syndrome biomarkers. Ped Nephrol. 2022; 37 (7): 1479–1493. doi: 10.1007/s00467- 022-05451-2.

35. Bresin E, Rurali E, Caprioli J, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013; 24 (3): 475–486. doi: 10.1681/ASN.2012090884.

36. Khandelwal P, Thomas Ch, Rathi B, et al. Membrane‐filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety. J Clin Apher. 2019; 34 (5): 555–562. doi: 10.1002/jca. 21711.

37. Menne J, Delmas Y, Fakhouri F, et al. Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study. BMC Nephrol. 2019; 20 (1). doi: 10.1186/s12882-019- 1314-1.

38. Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021; 137 (18): 2438–2449. doi: 10.1182/blood. 2020009280.

39. Sabry W, Elemary M, Burnouf T, Seghatchian J, Goubran H. Vitamin B12 deficiency and metabolism-mediated thrombotic microangiopathy (MM-TMA). Transf Apher Sci. 2020; 59 (1). doi: 10.1016/j.transci.2019.102717.

40. Duineveld C, Wetzels J. Complement inhibitors are not useful in secondary hemolytic uremic syndromes. Kidney Int. 2019; 96 (4): 829–833. doi: 10.1016/j.kint.2019.08.001.

41. Bláhová K, Janda J, Kreisinger J, Matějková E, Šedivá A. Long-term follow-up of Czech children with D hemolytic-uremic syndrome. Ped Nephrol. 2002; 17 (6): 400–403. doi: 10.1007/ s00467-002-0836-z.

42. Werion A, Storms P, Zizi Y, et al. Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies. Clin J Am Soci Nephrol. 2023; 18 (7): 881–891. doi: 10.2215/CJN.0000000000000182.

43. Wright R, Bannerman F, Beresford M, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol. 2020; 21 (1): 245. doi: 10.1186/s12882- 020-01888-5.

44. Kello N, Khoury L, Marder G, Furie R, Ekaterini Zapantis E, Horowitz D. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature. Sem Arthr Rheum. 2019; 49 (1): 74–83. doi: 10.1016/j.semarthrit.2018.11.005.

45. Timmermans S, Wérion A, Damoiseaux J, Morelle J, Reutelingsperger Ch, Van Paassen P. Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy. Hypertension. 2020; 75 (2): 422–430. doi: 10.1161/HYPER- TENSIONAHA.119.13714.

46. Chen X, Zhang X, Wang Y, Suxia Wang S, Zhao M. Genetic, clinical, and pathological study of patients with severe hypertension-associated renal microangiopathy. J Nephrol. 2023; 36 (9): 2477–2490. doi: 10.1007/s406 20-023-01644-6.

PODÍL NA PŘÍPRAVĚ RUKOPISU

TŠ – napsání rukopisu a jeho revize

TZ – revize + korekce rukopisu

TS – podíl na rukopisu kapitoly o infekcí podmíněné TMA, revize + korekce rukopisu

ČESTNÉ PROHLÁŠENÍ

Autoři práce prohlašují, že v souvislosti s tématem, vznikem a publikací tohoto článku nejsou ve střetu zájmů a vznik ani publikace článku nebyly podpořeny žádnou farmaceutickou firmou.

Do redakce doručeno dne: 28. 11. 2023.

Přijato po recenzi dne: 8. 7. 2024.

doc. MUDr. Mgr. Terezie Šuláková, Ph.D.

Klinika dětského lékařství

LF OU a FN Ostrava

17.listopadu 1790

708 52 0strava – Poruba

e-mail: terezie.sulakova@fno.cz